Published Date: 02 Mar 2023
High-risk melanoma patients who received the drug pembrolizumab before or after surgery to remove the cancer had a higher risk of developing melanoma than those who did not have a similar condition that eliminated cancer cells.
Read Full NewsPrograms offering telehealth counseling and nicotine replacement products should be part of routine oncology care, researchers say.
Researchers evaluate minimal residual disease status in 128 adults with relapsed or refractory follicular lymphoma treated with epcoritamab.
A new study explores whether germline profiling could refine the subclassification and prognosis of therapy-related myeloid neoplasms beyond treatment history alone.
1.
Analysis of NRG trial in limited-stage small cell lung cancer suggests QOL benefit with twice- vs. once-daily radiation
2.
A prostate cancer risk prediction algorithm could help target men at highest risk
3.
Off-the-Shelf Drug Matches CAR-T Effects in Refractory Lupus
4.
Hemihedral resection not necessary for neuroendocrine surgery after appendicitis
5.
New PET tracer enables same-day imaging of triple-negative breast and urothelial cancers
1.
Advances in Cancer Detection: From Genetic Risk to Molecular Biomarkers
2.
Emerging Frameworks in Oncology in Clinical Decision-Making
3.
Functional Iron Reserve Screening Before Clinical Deficiency: Clinical Insights and Evidence-Based Strategies
4.
Screening Strategies in Oncology: A Subspecialty Guide to Early Detection and Better Outcomes
5.
The Complications and Treatments of Intraosseous Hemangioma - A Comprehensive Guide
1.
Asian Symposium on Advancement in Hematology and Oncology
2.
Asian Symposium on Advancement in Hematology and Oncology
3.
Asian Symposium on Advancement in Hematology and Oncology
4.
International Cancer Conference
5.
Asian Symposium on Advancement in Hematology and Oncology
1.
Iron Deficiency Anemia: Ferric Maltol As a New Treatment Option- Further Discussion on A New Perspective
2.
Exploring the Hospitalization Burden in Refractory and Relapsed ALL
3.
Pazopanib Takes Center Stage in Managing Renal Cell Carcinoma - Part II
4.
The Evolving Landscape of First-Line Treatment for Urothelial Carcinoma
5.
Navigating the Complexities of Ph Negative ALL - Part IV
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation